# CEB-01 in Locally Resectable Pancreatic Cancer

Source: https://onco.cc/trials/nct06538857/  
OnCo record `nct06538857` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Standard surgery in pancreatic ductal adenocarcinoma, run by CEBIOTEX, now recruiting.

## Summary

CEB-01 in Locally Resectable Pancreatic Cancer is a phase 2 interventional study registered as NCT06538857 by CEBIOTEX, with 39 participants planned, started 2024-08-20 and due to reach its primary completion in 2028-09. Interventions recorded: Standard surgery and CEB-01.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06538857
- Phase: 2
- Setting: Exploratory Clinical Trial to Assess Safety, Tolerability Efficacy and Pharmacokinetics of CEB-01 PLGA Membrane in Participants With Pancreatic Cancer.
- Sponsor: CEBIOTEX
- Enrolled: 39

## Sources

- ClinicalTrials.gov NCT06538857: https://clinicaltrials.gov/study/NCT06538857

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [CEBIOTEX](https://onco.cc/companies/cebiotex/)

---
JSON: https://onco.cc/api/v1/entities/nct06538857.json